clinicum - Die klare Nummer 1 - clinicum digital
clinicum - Die klare Nummer 1 - clinicum digital
Description: Technology has potential to reimagine treatment for amblyopia (“lazy eye”), a leading cause of vision loss in children and young adults1Acquisition expands the Novartis refractive disorder pipeline in ophthalmology Basel, April 20, 2020 — Novartis announced today that it has completed the acquisition of Amblyotech, a US-based software startup, and will, in collaboration with Ubisoft and McGill University, pursue the development of the acquired digital technology for the treatment of amblyopia. Novartis is a
digital (14742) innovation (7882) eye care (469) novartis (80)
Learn about how Novartis is organized and our strategy, vision and mission. Meet our people and read about our commitments to diversity, equity and inclusion. Explore our history which goes back more than 250 years.
Patients and Caregivers
Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.
clinicum - Die klare Nummer 1 - clinicum digital
clinicum - Die klare Nummer 1 - clinicum digital